Renal effects of imidazole-2-hydroxybenzoate in patients with compensated liver cirrhosis

E. Lorenzano, S. Badalamenti, A. Scotti, I. Scaricabarozzi, B. Chinea, F. Salerno

Research output: Contribution to journalArticle


A double-blind crossover study versus placebo of the renal effects of the nonsteroidal anti-inflammatory drug imidazole 2-hydroxybenzoate was conducted in 10 patients with compensated liver cirrhosis. The administration of the drug (750 mg, t.i.d., for three days) did not affect renal plasma flow, glomerular filtration rate, free water clearance nor the urinary excretion of sodium or potassium. Values of plasma renin activity also did not change after drug administration. Direct tubular damage from imidazole 2-hydroxybenzoate was also excluded by normal excretion of beta-2-microglobulin and N-acetyl-beta-D-glucosaminidase. Urinary 6-keto-PGF1alpha output were comparable during imidazole 2-hydroxybenzoate and placebo administration. These data indicate that this nonsteroidal antiinflammatory drug does not affect the renal function in patients with compensated liver cirrhosis.

Original languageEnglish
Pages (from-to)225-229
Number of pages5
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Issue number7
Publication statusPublished - 1992


ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology

Cite this